Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Technology Process of Vorasidenib

Vorasidenib

Base Information
  • Chemical Name:Vorasidenib
  • CAS No.:1644545-52-7
  • Molecular Formula:C14H13ClF6N6
  • Molecular Weight:414.74
  • Hs Code.:
  • UNII:789Q85GA8P
  • NCI Thesaurus Code:C152914
  • Pharos Ligand ID:885N9SS38UJ5
  • ChEMBL ID:CHEMBL4279047
Vorasidenib

Synonyms:1,3,5-Triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-N2,N4-bis((1R)-2,2,2-trifluoro-1-methylethyl)-;6-(6-Chloro-2-pyridinyl)-N,N'-bis((2R)-1,1,1-trifluoro-2-propanyl)-1,3,5-triazine-2,4-diamine;vorasidenib

Suppliers and Price of Vorasidenib
Supply Marketing:
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • DC Chemicals
  • Vorasidenib(AG881) >98%
  • 100 mg
  • $ 500.00
  • DC Chemicals
  • Vorasidenib(AG881) >98%
  • 1 g
  • $ 1800.00
  • DC Chemicals
  • Vorasidenib(AG881) >98%
  • 250 mg
  • $ 900.00
  • ChemScene
  • Vorasidenib 99.87%
  • 50mg
  • $ 750.00
  • ChemScene
  • Vorasidenib 99.87%
  • 10mg
  • $ 250.00
  • ChemScene
  • Vorasidenib 99.87%
  • 5mg
  • $ 150.00
  • ChemScene
  • Vorasidenib 99.87%
  • 2mg
  • $ 90.00
  • ChemScene
  • Vorasidenib 99.87%
  • 100mg
  • $ 1100.00
  • Cayman Chemical
  • Vorasidenib
  • 5mg
  • $ 356.00
  • Cayman Chemical
  • Vorasidenib
  • 1mg
  • $ 89.00
Total 33 raw suppliers
Chemical Property of Vorasidenib
Chemical Property:
  • PKA:1.49±0.41(Predicted) 
  • XLogP3:5.3
  • Hydrogen Bond Donor Count:2
  • Hydrogen Bond Acceptor Count:12
  • Rotatable Bond Count:5
  • Exact Mass:414.0794411
  • Heavy Atom Count:27
  • Complexity:448
Purity/Quality:

99%, *data from raw suppliers

Vorasidenib(AG881) >98% *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:
Useful:
  • Canonical SMILES:CC(C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)NC(C)C(F)(F)F
  • Isomeric SMILES:C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F
  • Recent ClinicalTrials:Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas
  • Recent EU Clinical Trials:A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1644545-52-7

Total 8 Pictures about this product